Hong Kong stock market abnormal fluctuations | Wuxi Apptec (02359) is now up nearly 5%, with third-quarter revenue returning to over one hundred billion, and hand orders increasing by more than 35% year-on-year.

Wuxi Apptec (02359) is now up nearly 5%, as of the time of writing, up 4.81% to HK$56.5, with a turnover of 0.205 billion Hong Kong dollars.

Zhitong Finance21:33 ET

Zheshang: Innovative drugs and blood products sectors may benefit from slow demand recovery on the demand side.

Zheshang has released research reports stating that the transition of old and new dynamics in the pharmaceutical industry will continue in the future. Areas with innovative drugs, supply-side structural reform, or a good layout (innovative drugs supporting industry chain, large infusion solutions, potent anaesthetics, blood products, pharmaceutical circulation, traditional Chinese medicine OTC) could benefit from the slow recovery on the demand side, potentially showing better growth prospects.

Zhitong Finance17:40 ET

Hong Kong stocks are active | CRO concepts generally rise, medical insurance negotiations support innovative drugs, and under the environment of interest rate cuts, global biomedical financing will rebound.

The concept of CRO is generally on the rise. As of the time of publication, Asymchem Laboratories (06821) rose by 4.95%, to HKD 59.4; Tigermed (03347) rose by 4.94%, to HKD 38.25; Wuxi Apptec (02359) rose by 3.88%, to HKD 53.5.

Zhitong FinanceNov 5 01:34 ET

Express News | UBS Group AG's Long Position in H-Shares of WuXi AppTec Decreases to 4.91% on Oct 28 From 5.51% - HKEX

ReutersNov 1 05:26 ET

[Brokerage Focus] Citi raises the target price of Wuxi AppTec (02359) to HK$48, but uncertainties remain regarding the Mie Biosecurity Act.

Jingu Cai Xun | CITIC International issued a research report, indicating that Wuxi Apptec (02359) saw a year-on-year decrease of 6.2% in revenue to 27.7 billion yuan in the first three quarters, but excluding the revenue from the new crown project in 2023, the revenue increased by 4.6% year-on-year. Shareholders' net income in the first three quarters decreased by 19.1% year-on-year to 6.53 billion yuan, reflecting a 10.1% year-on-year decline in Non-IFRS adjusted net income reflecting the profitability of core business, to 6.68 billion yuan, with the year-on-year decline narrowing compared to the first half of the year. The performance of the main chemical business (accounting for over 70% of the company's revenue) improved in the third quarter, exceeding expectations slightly. Excluding

Jinwu Financial NewsOct 31 22:57 ET

Earnings Miss: WuXi AppTec Co., Ltd. Missed EPS By 6.0% And Analysts Are Revising Their Forecasts

Simply Wall StOct 30 18:30 ET